Subscribe

Alamar Biosciences Launches National Study on Neurodegenerative Biomarkers

· By Bernal Fintech Markets Desk

Alamar Biosciences, a leader in precision proteomics, has launched a national research initiative in collaboration with multiple top-tier research universities to advance the discovery and validation of blood-based biomarkers for neurodegenerative diseases. The study will use Alamar’s NULISAseq Neuro 220 test kit to analyze approximately 21,000 plasma samples from 10,000 participants with Alzheimer’s disease and related dementias (ADRD). The data generated will be made publicly available through the National Alzheimer’s Coordinating Center (NACC) and will be used in a national data competition to support AI-driven research.

The initiative is part of the CLARiTI (CLARifying ADRD through Imaging) project, which aims to improve the understanding of neurodegenerative disease mechanisms through multi-center collaboration. The study is led by researchers from Washington University, University of Wisconsin, and Indiana University, with support from Alzheimer’s Association, Robertson Foundation, and an anonymous foundation. The data will be accessible to the global research community and will be linked to longitudinal data from Alzheimer’s Disease Research Centers (ADRCs) across the U.S.

Research Methodology and Objectives

The study will use Alamar’s NULISAseq Neuro 220 test kit, which includes a new eMTBR-Tau detection module. This kit enables the detection of multiple biomarkers related to neurodegenerative diseases and neuroinflammation, including tau protein tangles, α-synuclein biology, and other protein aggregation markers. The test kit provides the largest number of brain-derived tau protein targets, allowing researchers to study multiple disease pathways in the same cohort of participants with comprehensive data.

The initiative aims to create an open-access proteomics dataset that can be linked to NACC identifiers. This will allow researchers to combine new proteomics data with existing longitudinal data from ADRCs, covering clinical, cognitive, neuroimaging, genetic, genomic, and neuropathological data. AI and computational research teams will use multi-modal analysis methods to explore disease subtyping, biomarker discovery, and disease progression prediction.

What it means for markets

The initiative positions Alamar Biosciences at the forefront of precision proteomics and neurodegenerative disease research. The open-access data and AI-driven approach may accelerate the discovery of biomarkers and therapeutic targets, potentially enhancing the company’s market position in the growing field of early disease detection and personalized medicine.

Sources

More Tech news →